This EU-based KOL provides an in-depth understanding of the market dynamics in the region. In this discussion, the KOL points out the unmet needs in Crohn’s disease and ulcerative colitis, and speaks on the future prospects of both marketed drugs and those in late-stage clinical trials. The KOL also weighs in on the debate between oral small molecules versus biologics in IBD. 

This interview was conducted on 27 November 2023. 

If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.